Pharmaceutical Firm Boehringer Ingelheim Caps Out-of-Pocket Inhaler Costs at $35 a Month

Pharmaceutical company Boehringer Ingelheim will cap patients’ out-of-pocket costs at $35 per month for all of its inhaler products and devices, officials announced on March 7. The cap will begin on June 1 and will apply to eligible patients, the German drugmaker said in a statement. Officials said the move will “dramatically decrease costs” at retail pharmacies for the most vulnerable patients, including those who are uninsured or underinsured. The cap on out-of-pocket costs “reinforces the company’s long-standing commitment to ensure access to important medicines for patients,” Boehringer Ingelheim said. “Patients have counted on Boehringer Ingelheim for nearly 140 years to tackle challenges across diseases, including respiratory illnesses,” said Jean-Michel Boers, President and CEO, Boehringer Ingelheim USA Corporation. “The U.S. healthcare system is complex and often doesn’t work for patients, especially the most vulnerable.”...